ARES CAPITAL CORP 8-K

What Happened
Ares Capital Corporation filed an 8-K (dated May 26, 2026) reporting that on May 21, 2026 it amended and restated its senior secured credit facility (the A&R Credit Facility) with JPMorgan Chase Bank, N.A. as administrative agent. The amendment modestly increased total commitments from about $5.312 billion to about $5.481 billion, restated pricing to reference Term SOFR, and extended the revolving and term loan maturities for lenders that elected to extend.

Key Details

• Amendment date: May 21, 2026; 8‑K filed May 26, 2026.
• Total commitments increased from ≈ $5.312B to ≈ $5.481B. Facility now composed of ~ $4.3B revolving tranche and ~ $1.2B term loan tranche.
• Maturities/extensions for electing lenders (≈ $4.2B): revolving period extended from Apr 15, 2029 → May 21, 2030; stated maturity extended from Apr 15, 2030 → May 21, 2031. Term loan maturities for electing lenders also extended to May 21, 2031. Some lenders (small portions) did not extend and keep earlier maturities (specific amounts and dates disclosed).
• Pricing: base rate moved to Term SOFR (or alternate rate) plus spreads that vary by lender group and monthly borrowing base metrics (example SOFR spreads for extending/special non‑extending lenders: 1.525% / 1.650% / 1.775%; other lenders: 1.750% / 1.875%). Commitment fees: 0.325% (extending/special) or 0.375% (other). Letter of credit fees range from 1.775%–2.025% (tiered).
• Other terms: secured by a material portion of the company’s assets, guaranteed by certain subsidiaries; borrowing base with advance rates by asset type; $450M L/C sub‑limit and $300M swingline sub‑limit; asset coverage covenant requiring assets-to-indebtedness ratio ≥ 1.5:1.0. Exhibit 10.1 contains the full agreement.

Why It Matters
The amendment keeps Ares Capital’s primary liquidity and borrowing capacity largely intact (a large revolving line and $1.2B term loan) and pushes many maturities out by roughly one year for lenders that consented, reducing near‑term refinancing pressure for most of the facility. At the same time, pricing is tied to Term SOFR with lender-specific spreads and modest commitment/L/C fees, so borrowing costs and usage economics are defined more clearly. Investors should note the continued collateral security, the borrowing‑base and covenant constraints (including an asset coverage ratio), and the accordion option that could expand capacity in the future. The full credit agreement is filed as Exhibit 10.1 to the 8‑K.